Advanced search
Publication Cover
Acta Oncologica Volume 56, 2017 - Issue 3
Journal homepage
5,080
Views
36
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLES: LUNG CANCER

Real-world data on nivolumab treatment of non-small cell lung cancer

O.T. BrustugunDepartment of Oncology, Oslo University Hospital The Norwegian Radium Hospital, Oslo, Norway; ;Department of Cancer Genetics, Oslo University Hospital – The Norwegian Radium Hospital, Oslo, NorwayCorrespondence[email protected]
,
M. SprautenDepartment of Oncology, Oslo University Hospital The Norwegian Radium Hospital, Oslo, Norway;
&
Å. HellandDepartment of Oncology, Oslo University Hospital The Norwegian Radium Hospital, Oslo, Norway; ;Department of Cancer Genetics, Oslo University Hospital – The Norwegian Radium Hospital, Oslo, Norway
Pages 438-440 | Received 22 Jul 2016, Accepted 20 Oct 2016, Published online: 28 Nov 2016

References

  • Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–1639.
  • Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–135.
  • Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–1550.
  • Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387:1837–1846.
  • Saturni S, Bellini F, Braido F, et al. Randomized controlled trials and real life studies. approaches and methodologies: a clinical point of view. Pulm Pharmacol Ther. 2014;27:129–138.
  • Böhm S, Montfort A, Pearce OM, et al. Neoadjuvant chemotherapy modulates the immune microenvironment in metastases of tubo-ovarian high-grade serous carcinoma. Clin Cancer Res. 2016;22:3025–3036.
  • Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018–2028.
  • Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589–1597.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.